Abstract
Background Approximately one third of recently diagnosed Parkinson’s disease (PD) patients experience cognitive decline. The nucleus basalis of Meynert (NBM) degenerates early in PD and is crucial for cognitive function. The two main NBM white matter pathways include a lateral and medial trajectory. However, research is needed to determine which pathway, if any, are associated with PD-related cognitive decline.
Methods Thirty-seven PD patients with no mild cognitive impairment (MCI) were included in this study. Participants either developed MCI at 1-year follow up (PD MCI-Converters; n=16) or did not (PD no-MCI; n=21). Mean diffusivity (MD) of the medial and lateral NBM tracts were extracted using probabilistic tractography. Between-group differences in MD for each tract was compared using ANCOVA, controlling for age, sex, and disease duration. Control comparisons of the internal capsule MD were also performed. Associations between baseline MD and cognitive outcomes (working memory, psychomotor speed, delayed recall, and visuospatial function) were assessed using linear mixed models.
Results PD MCI-Converters had significantly greater MD of both NBM tracts compared to PD no-MCI (p<.001). No difference was found in the control region (p=.06). Trends were identified between: 1) lateral tract MD, poorer visuospatial performance (p=.05) and working memory decline (p=.04); and 2) medial tract MD and reduced psychomotor speed (p=.03).
Conclusions Reduced integrity of the NBM tracts is evident in PD patients up to one year prior to the development of MCI. Thus, deterioration of the NBM tracts in PD may be an early marker of those at risk of cognitive decline.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including, Abbvie, AcureX, Allergan, Amathus, Therapeutics, Asap, Avid, Biogen, Bial Biotech, Biolegend, BlueRock Therapeutics, Bristol-Myers, Calico, Celgene, Cerevel, Coave Therapeutics, Dacapo BrainScience, Jenali Therapeutics, 4D Pharma plc, GE Healthcare, Edmond J. Safra Philanthropic Foundation, Genentech, GlaxoSmithKline, Golub Capital, Gain Therapeutics, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merch, MSD Veso Scale Discovery, Neuroscine Biosciences, Pfizer, Piramal Healthcare, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, and Yumanity Therapeutics. The authors are funded by two National Institutes of Health (NIH): National Institute of Neurological Disorders and Stroke (NINDS) research grants (RAC, KBW and HMBS: UG3NS128150; SA and HMBS: UH3NS107709).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data). For up-to-date information on the study, visit www.ppmi-info.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interest: The authors have no conflicts of interest to disclose.
Funding for Study: PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including, Abbvie, AcureX, Allergan, Amathus, Therapeutics, Asap, Avid, Biogen, Bial Biotech, Biolegend, BlueRock Therapeutics, Bristol-Myers, Calico, Celgene, Cerevel, Coave Therapeutics, Dacapo BrainScience, Jenali Therapeutics, 4D Pharma plc, GE Healthcare, Edmond J. Safra Philanthropic Foundation, Genentech, GlaxoSmithKline, Golub Capital, Gain Therapeutics, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merch, MSD Veso Scale Discovery, Neuroscine Biosciences, Pfizer, Piramal Healthcare, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, and Yumanity Therapeutics.
Data Availability
Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data). For up-to-date information on the study, visit www.ppmi-info.org.
